Aldosterone Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Aldosterone Antagonist The report assesses ...
January 2022
60 pages
Alpha 4 Beta 2 Neuronal Nicotinic Receptor (NNR) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha 4 Beta 2 Neuronal Nicotinic Receptor (NNR) Agonist The ...
January 2022
60 pages
Alpha 4 Beta 7 (A4b7) Integrin Inhibitor- - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha 4 Beta 7 (A4b7) Integrin Inhibitor- The report ...
January 2022
60 pages
Alpha Glucosidase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha Glucosidase Inhibitor The report assesses ...
January 2022
60 pages
Alpha Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha Receptor Agonist The report assesses ...
January 2022
60 pages
Alpha Receptor Antagonist - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha Receptor Antagonist The report assesses ...
January 2022
120 pages
Alpha v Beta 3/5/6 Integrin Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha v Beta 3/5/6 Integrin Antagonist The report ...
January 2022
60 pages
Alpha v Beta 3 Integrin Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha v Beta 3 Integrin Antagonist The report ...
January 2022
60 pages
Alpha v Beta 5 Integrin Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha v Beta 5 Integrin Antagonist The report ...
January 2022
60 pages
Alpha-1 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha-1 Agonist The report assesses the active Alpha-1 Agonist ...
January 2022
60 pages
Alpha-1 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha-1 Antagonist ...
January 2022
60 pages
Alpha-1A Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha-1A Antagonist The report assesses ...
January 2022
60 pages
Alpha-2 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha-2 Agonist The report assesses the active Alpha-2 Agonist ...
January 2022
60 pages
Alpha-2 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha-2 Antagonist ...
January 2022
60 pages
Alpha-Amylase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha-Amylase Inhibitor The report assesses ...
January 2022
60 pages
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Alpha-Synuclein (alphaSyn or SNCA) Inhibitor The report ...
January 2022
60 pages
AMPA Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “AMPA Receptor Antagonist The report assesses ...
January 2022
60 pages
Amyloid Protein Blockers - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Amyloid Protein Blockers The report assesses ...
January 2022
60 pages
Anaplastic lymphoma kinase inhibitors - Pipeline Insight, 2022
US$ 1,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anaplastic Lymphoma Kinase (ALK) Inhibitor The report ...
January 2022
60 pages
Androgen Agonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Androgen Agonist The report assesses the active Androgen Agonist ...
January 2022
60 pages
Androgen Antagonist - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Androgen Antagonist The report assesses ...
January 2022
90 pages
Angiopoietin Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Angiopoietin Inhibitor The report assesses ...
January 2022
60 pages
Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Angiopoietin 2 (Ang-2) Inhibitor The report ...
January 2022
60 pages
Angiotensin Converting Enzyme (ACE) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Angiotensin Converting Enzyme (ACE) Inhibitor The ...
January 2022
60 pages
Angiotensin II Receptor Type 2 (AT2 Receptor) Modulator - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Angiotensin II Receptor Type 2 (AT2 Receptor) Modulator The ...
January 2022
60 pages
Angiotensin II Receptor Type 2 (AT2 Receptor) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Angiotensin II Receptor Type 2 (AT2 Receptor) Inhibitor The ...
January 2022
60 pages
Angiotensin Modulators - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Angiotensin Modulators The report assesses ...
January 2022
60 pages
Angiotensin Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Angiotensin Receptor Agonist The report assesses ...
January 2022
60 pages
Anti GM-CSF Antibody - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti GM-CSF Antibody The report assesses the active Anti GM-CSF ...
January 2022
60 pages
Anti-CD152 Antibody - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-CD152 Antibody The report assesses the active Anti-CD152 ...
January 2022
60 pages
Anti-CD19 Antibody - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-CD19 Antibody The report assesses the active Anti-CD19 ...
January 2022
60 pages
Anti-CD274 (PD-L1) Antibody - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-CD274 (PD-L1) Antibody The report assesses ...
January 2022
90 pages
Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2022
US$ 2,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-CD279 (PD-1) Antibody The report assesses ...
January 2022
90 pages
Anti-CD28 Antibody - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-CD28 Antibody The report assesses the active Anti-CD28 ...
January 2022
60 pages
Anti-CD3 Antibody - Pipeline Insight, 2022
US$ 1,500.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-CD3 Antibody The report assesses the active Anti-CD3 Antibody ...
January 2022
90 pages
Anti-CD33 Antibody - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-CD33 Antibody The report assesses the active Anti-CD33 ...
January 2022
60 pages
Anti-CD37 Antibody - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-CD37 Antibody The report assesses the active Anti-CD37 ...
January 2022
60 pages
Anti-CD38 Antibody - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-CD38 Antibody The report assesses the active Anti-CD38 ...
January 2022
60 pages
Anti-CD40 Antibody - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-CD40 Antibody The report assesses the active Anti-CD40 ...
January 2022
60 pages
Anti-CD52 Antibody - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-CD52 Antibody The report assesses the active Anti-CD52 ...
January 2022
60 pages
Anti-CD80 Antibody - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-CD80 Antibody The report assesses the active Anti-CD80 ...
January 2022
60 pages
Anti-Dickkopf-1 (Dkk-1) Antibody - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-Dickkopf-1 (Dkk-1) Antibody The report ...
January 2022
60 pages
Anti-Lymphotoxin - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-Lymphotoxin The report assesses the active Anti-Lymphotoxin ...
January 2022
60 pages
Anti-Mucin 1 (MUC1) Antibody - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Anti-Mucin 1 (MUC1) Antibody The report assesses ...
January 2022
60 pages
Apolipoprotein B (ApoB) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Apolipoprotein B (ApoB) Inhibitor The report ...
January 2022
60 pages
Apoptosis Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Apoptosis Inhibitor The report assesses ...
January 2022
60 pages
Arginine Depletors - Pipeline Insight, 2022
US$ 1,250.00
... product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Arginine Depletors ...
January 2022
60 pages
ATPase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “ATPase Inhibitor The report assesses the active ATPase Inhibitor ...
January 2022
60 pages
Aurora Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Aurora Kinase Inhibitor The report assesses ...
January 2022
60 pages
